Co-Authors
This is a "connection" page, showing publications co-authored by ANA APARICIO and SUMIT K. SUBUDHI.
Connection Strength
1.902
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jul 01; 30(13):2751-2763.
Score: 0.243
-
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na?ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021 10; 9(10).
Score: 0.201
-
RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. J Immunother Precis Oncol. 2020 Aug; 3(3):128-132.
Score: 0.183
-
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537).
Score: 0.181
-
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443.
Score: 0.174
-
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924.
Score: 0.142
-
Immune Checkpoint Therapies in Prostate Cancer. Cancer J. 2016 Mar-Apr; 22(2):117-20.
Score: 0.136
-
Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer. 2024 Dec 01; 31(12).
Score: 0.062
-
Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis. 2024 Jul 17.
Score: 0.061
-
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. Clin Cancer Res. 2024 May 15; 30(10):2272-2285.
Score: 0.060
-
Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience. Cardiooncology. 2023 Sep 13; 9(1):33.
Score: 0.058
-
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267.
Score: 0.050
-
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 08 02; 4(8):e2122998.
Score: 0.050
-
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7).
Score: 0.049
-
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5.
Score: 0.046
-
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75.
Score: 0.045
-
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
Score: 0.045
-
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell. 2019 Nov 14; 179(5):1177-1190.e13.
Score: 0.044
-
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
Score: 0.040
-
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene. 2015 Oct; 34(43):5411-7.
Score: 0.032